Natco Pharma marketing partner launches generic version of Afinitor in US
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company's marketing partner Breckenridge Pharmaceutical, Inc., US has launched the l0 mg strength of Everolimus Tablets (generic for Afinitor'" ) in the US market.
The U.S. Food and Drug Administration (USFDA) previously granted final approval of this Abbreviated New Drug Application.
According to industry sales data, the l0 mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021.
Breckenridge previously launched Everolimus tablets in 2.5 mg, 5 mg and 7.5 mg strengths during the first quarter of 2021 in the US market.
Read also: Natco Pharma arm launches first generic alternative to Revlimid in Canada
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.